Outcome of Board meeting held today i.e., Thursday, 11th December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Hemo Organic Ltd, at its meeting on 11th December 2025, approved three key items. First, an increase in authorised share capital from Rs. 10 crore to Rs. 13.45 crore (creating 34.50 lakh new equity shares of Rs. 10 each). Second, raising of funds up to Rs. 12,46,87,500 through the issue of up to 99,75,000 convertible warrants to non-promoter category entities at Rs. 12.50 per warrant (Rs. 10 face value + Rs. 2.50 premium), each convertible into one equity share within 18 months, with 25% upfront payment. Third, an Extra-Ordinary General Meeting (EGM) on 7th January 2026 to seek shareholder approval. The warrants are proposed to be allotted to three allottees: Managing Director Vishwambar Kameshwar Singh (33 lakh warrants), Vacro Enterprises Pvt Ltd (33.5 lakh warrants), and Qmin Realities Pvt Ltd (33.25 lakh warrants), increasing their combined holding to 74.26% post-issue.
Existing shareholders will face significant dilution if all warrants are converted — the three allottees together will hold 74.26% of the expanded equity base. The issue price of Rs. 12.50 is at a modest premium to face value, and conversion depends on the allottees paying the balance 75%, so fundraising success is not guaranteed. The MD subscribing under the 'non-promoter' category is unusual and may warrant closer scrutiny regarding his promoter status going forward.